Vertex Pharmaceuticals and Lonza are partnering in the production of a new facility. Both companies are working together to manufacture and support the production of Vertex’s experimental cell therapy VX-880 for Type 1 diabetes and a second candidate VX-264.
The companies are planning to co-invest in construction of a new facility in Portsmouth, NH which is planned to kick of later this year. Lonza is expected to employ up to 300 employees within a 130,000 square foot space.
This occurs six months after Lonza completes the expansion of two of its production facilities in Oregon, and five months after opening a new early development services lab in Cambridge, MA.
